Literature DB >> 11133821

Correlation of defective mitotic checkpoint with aberrantly reduced expression of MAD2 protein in nasopharyngeal carcinoma cells.

X Wang1, D Y Jin, Y C Wong, A L Cheung, A C Chun, A K Lo, Y Liu, S W Tsao.   

Abstract

Nasopharyngeal carcinoma (NPC) occurs with a high incidence in many countries in south-eastern Asia. Chromosomal abnormalities have been commonly found in NPC, but the underlying mechanism is not well understood. We determined mitotic indices, the staining pattern of nuclear DNA and cell cycle profiles of NPC cells in response to treatment with microtubule-disrupting agents, and found that the mitotic checkpoint was defective in two out of five (40%) of the tested NPC cell lines. We also observed that an aberrantly reduced expression of MAD2, one of the key components of mitotic checkpoint, correlated with the loss of checkpoint control. Our findings suggest that a defective mitotic checkpoint characterized by reduced expression of MAD2 contributes to chromosomal instability in NPC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11133821     DOI: 10.1093/carcin/21.12.2293

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  24 in total

Review 1.  Let's huddle to prevent a muddle: centrosome declustering as an attractive anticancer strategy.

Authors:  A Ogden; P C G Rida; R Aneja
Journal:  Cell Death Differ       Date:  2012-06-01       Impact factor: 15.828

Review 2.  Mechanisms of chromosomal instability.

Authors:  Sarah L Thompson; Samuel F Bakhoum; Duane A Compton
Journal:  Curr Biol       Date:  2010-03-23       Impact factor: 10.834

3.  Mitotic checkpoint function in the formation of gross chromosomal rearrangements in Saccharomyces cerevisiae.

Authors:  Kyungjae Myung; Stephanie Smith; Richard D Kolodner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-28       Impact factor: 11.205

4.  Depression of MAD2 inhibits apoptosis and increases proliferation and multidrug resistance in gastric cancer cells by regulating the activation of phosphorylated survivin.

Authors:  Li Wang; Fang Yin; Yulei Du; Bei Chen; Shuhui Liang; Yongguo Zhang; Wenqi Du; Kaichun Wu; Jie Ding; Daiming Fan
Journal:  Tumour Biol       Date:  2010-05-04

5.  Chromosomal instability is associated with higher expression of genes implicated in epithelial-mesenchymal transition, cancer invasiveness, and metastasis and with lower expression of genes involved in cell cycle checkpoints, DNA repair, and chromatin maintenance.

Authors:  Anna V Roschke; Oleg K Glebov; Samir Lababidi; Kristen S Gehlhaus; John N Weinstein; Ilan R Kirsch
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

6.  A dominant interfering Bub1 mutant is insufficient to induce or alter thymic tumorigenesis in vivo, even in a sensitized genetic background.

Authors:  Dale O Cowley; Ginger W Muse; Terry Van Dyke
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  Complete loss of the tumor suppressor MAD2 causes premature cyclin B degradation and mitotic failure in human somatic cells.

Authors:  Loren Michel; Elena Diaz-Rodriguez; Gopeshwar Narayan; Eva Hernando; Vundavalli V V S Murty; Robert Benezra
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

8.  BUB3 that dissociates from BUB1 activates caspase-independent mitotic death (CIMD).

Authors:  Y Niikura; H Ogi; K Kikuchi; K Kitagawa
Journal:  Cell Death Differ       Date:  2010-01-08       Impact factor: 15.828

9.  Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma.

Authors:  Valeria De Giorgi; Alessandro Monaco; Andrea Worchech; Marialina Tornesello; Francesco Izzo; Luigi Buonaguro; Francesco M Marincola; Ena Wang; Franco M Buonaguro
Journal:  J Transl Med       Date:  2009-10-12       Impact factor: 5.531

10.  Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro.

Authors:  M Prencipe; P Fitzpatrick; S Gorman; M Tosetto; M Mosetto; R Klinger; F Furlong; M Harrison; D O'Connor; I B Roninson; J O'Sullivan; A McCann
Journal:  Br J Cancer       Date:  2009-12-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.